Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease

Neurology

Volumn 50, Issue 5, 1998, Pages 1222-1230

  Morris, John C ^a,c   Cyrus, Pamela A ^b   Orazem, John ^b   Mas, Janice ^b   Bieber, Florian ^b   Ruzicka, Bianca B ^b   Gulanski, Barbara ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b BAYER CORPORATION   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRIFONATE;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HUMAN; LEG CRAMP; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PALLIATIVE THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; TREATMENT OUTCOME; VOMITING;

EID: 0031842293     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.5.1222     Document Type: Article

References (43)

1. Cummings JL, Benson DF. Dementia: a clinical approach, 2nd ed. Boston: Heinemann-Butterworth, 1992.
2. Beard CM, Kokmen E, O'Brien PC, Kurland LT. The prevalence of dementia is changing over time in Rochester, Minnesota. Neurology 1995;45:75-79.
3. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987;76:465-479.
4. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989;262:2551-2556.
5. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
6. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126.
7. Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977;1:189-191.
8. Perry EK, Tomlinson BE, Blessed G, Bergman K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2:1457-1459.
9. Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974;30:113-121.
10. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-2529.
11. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
12. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhof LT, the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
13. Galasko DR, Thai LJ. Cholinomimetic agents. In: Cummings JL, Miller BL, eds. Alzheimer's disease. Treatment and long-term management. New York: Marcel Dekker, 1990:23-36.
14. Bodick NC, Offen WW, Levey A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 1997;54:465-473.
15. Cerf J, Lebrun A, Dierichx J. A new approach to helminthiasis control: the use of an organophosphorus compound. Am J Trop Med Hyg 1962;11:514-517.
16. Holmstedt B, Nordgren I, Sandoz M, Sundwall A. Metrifonate. A summary of toxicological and pharmacological information available. Arch Toxicol 1978;41:3-29.
17. Nordgren I, Bergstrom M, Holmstedt B, Sandoz M. Transformation and action of metrifonate. Arch Toxicol 1978;41:31-41.
18. Hinz VC, Grewig S, Schmidt BH. Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res 1996;21:331-337.
19. Hinz VC, Grewig S, Schmidt BH. Metrifonate and dichlorvos: effects of a single oral administration on cholinesterase activity in rat brain and blood. Neurochem Res 1996;21:339-345.
20. Schmidt BH, Hinz VC, Blokland A, van der Staay F-J, Fanelli R. Preclinical pharmacology of metrifonate: a promise for Alzheimer therapy. In: Becker R, Giacobini E, Robert P, eds. Alzheimer disease: from molecular biology to therapy. Boston: Birkhäuser, 1996:217-221.
21. Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman and Gilman's the pharamacologic basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996:161-176.
22. Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer disease: report of an open trial. Drug Dev Res 1990;19:425-434.
23. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
24. Cummings JL, Cyrus P, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50.
25. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:39-44.
26. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
27. Rosen WG, Terry RD, Fuld P, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
28. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, revised. Washington, DC: American Psychiatric Association, 1994.
29. Leber P. Guidelines for the clinical evaluation of antidementia drugs. Washington, DC: Food and Drug Administration, 1990.
30. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-2321.
31. Thai LJ, Schwartz G, Sano M, et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease Neurology 1996;47:1389-1395.
32. Rockwood K, Morris JC. Global staging measures in dementia. In Gauthier S, ed. Clinical diagnosis and management of Alzheimer's disease. London: Martin Dunitz Limited, 1996: 141-153.
33. Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
34. Reisberg B, Ferris SH, De Leon MJ, Crook T. A Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139.
35. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
36. Aronson MK, Post DC, Guastadisegni P. Dementia, agitation and care in the nursing home. J Am Geriatr Soc 1993;41:507-512.
37. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6.
38. Tracy JW, Webster LT Jr. Drugs used in the chemotherapy of helminthiasis. In: Hardman JG, Limbird LE, Molinoff PB, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996: 1009-1026.
39. Hallak M, Giacobini E. A comparison of the effects of two inhibitors on brain cholinesterase. Neuropharm 1987;26:521-530.
40. Pacheco G, Palacios-Esquivel R, Moss DE. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease. Selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. J Pharmacol Exp Ther 1995;274:767-770.
41. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-1222.
42. Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer disease. Lancet 1996;348:429-432.
43. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies Neurology 1996;47:425-432.